PNI will use the investment to advance a best-in-class COVID-19 mRNA vaccine candidate to clinical trials.
PNI provides over 250 industry and academic partners with solutions for the development of vaccines, gene therapies, and cell therapies, in the areas of infectious diseases, oncology and rare diseases.
With this investment from the government of Canada, PNI's chief scientific officer, Dr. Andrew Geall, and his team will use their technology platforms and expertise in self-amplifying mRNA vectors, lipid-based drug delivery systems and nanomedicine manufacturing to develop a cost-effective COVID-19 vaccine.
As part of Canada's efforts to combat COVID-19, the Strategic Innovation Fund is working diligently to support projects led by the private sector for COVID-19 related vaccine and therapy clinical trials to advance Canada's medical countermeasures in the fight against COVID-19.
Bringing together its proprietary technology platforms, key partnerships and unparalleled expertise in nanomedicines, PNI is excited to be leading the development of a Made-in-Canada COVID vaccine.
Precision NanoSystems is in developing the next wave of genetic medicines in infectious diseases, cancer and rare diseases.
We work with the world's leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine.
PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genetic medicines.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval